ClinicalTrials.gg
RecruitingNCT05582499FASCINATE-NUpdated May 28, 2026

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

A Phase 2 interventional study of Dalpiciclib and Pyrotinib in Breast Neoplasm, Breast Cancer and Breast Tumors, sponsored by Fudan University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 64 judgments

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
716
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.

Planned enrollment
6th of 62
716 · median 110
Started
2022
with 4 others
Phase 2
41 of 65
20 open now
Primary completion
2027-12
later than 22 of 38 live
Registered
31st of 65
by date

Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is the 6th largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2022, is one of 41 in phase 2, reaches primary completion later than 22 of the 38 other live ones, and was the 31st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

Where they have run

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Triple Negative Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

Read the detailed description

FASCINATE-N is a platform that will compare the efficacy of novel drugs alone or in combination with standard chemotherapy with the efficacy of standard therapy alone. The goal is to identify improved treatment regimens for subsets on the basis of clinical subtyping. In this trial, breast cancer patients eligible for inclusion can be randomly divided into the precision treatment group and conventional neoadjuvant chemotherapy group according to molecular typing and subtyping. The research therapy arm can be updated with the update of basic translational research in our center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs. As described for previous adaptive trials, regimens that show to be more effective than standard therapy will graduate from the trial with their corresponding biomarker signature(s). Regimens will be dropped if they show a low probability of improved efficacy with any biomarker signature. New drugs will enter as those that have undergone testing complete their evaluation.

03

Conditions studied

  • Breast Neoplasm
  • Breast Cancer
  • Breast Tumors
  • Triple-Negative Breast Cancer (TNBC)
  • HER2-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive Tumor
  • Hormone Receptor Negative Tumor
  • Early-stage Breast Cancer
  • Locally Advanced Breast Cancer

Browse trials for

04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 716 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive breast cancer of clinical stage T1-4N1-3M0 or cT2-4N0M0;
  • Age between18-70 years;
  • (ECOG) performance status 0-1;
  • ER, PR and status were measured by immunohistochemistry (IHC);
  • ≥55%;
  • Definition of SNF subtypes: SNF subtypes confirmed by digital pathology of H\&E slices;
  • Triple negative subtyping: On the basis of triple-negative pathological diagnosis, AR, cluster of differentiation 8 (CD8) and Forkhead Box C1 (FOXC1) were combined to define the subtyping;
  • At least one according to version 1.1
  • Normal organ and marrow function: (HB) ≥90 g/L (No blood was transfused within 14 days), ≥ 1500/μL, ≥ 75,000/μL, Total ≤ 1.5 x ), (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) ≤ 3 x ULN, creatinine \< 1 x ULN, endogenous > 50 ml/min (Cockcroft-Gault formula);
  • Non-pregnant and non-lactating, fertile female subjects were required to use a medically approved method for the duration of the study treatment and at least 3 months after the last use of the study drug;
  • Ability to understand and willingness to sign a written

Exclusion criteria

Exclusion Criteria:

  • Previous cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason;
  • Patients with (NYHA) grade II or above heart disease (including grade II);
  • Patients with severe systemic infections or other serious diseases;
  • Patients with known allergy or intolerance to the study drug or its ;
  • Other malignant tumors in the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer;
  • Pregnant or lactating patients of childbearing age who refused to take appropriate measures during the course of the study;
  • Participated in other trial studies within 30 days before the administration of the first dose of the study drug;
  • Patients who were judged by the investigator to be unsuitable for this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
716 participants (estimated)

Study arms

  • Experimental
    L1-1

    If patients were hormone receptor-positive (HR+) and HER2-negative (HER2-) defined as similarity network fusion 1(SNF1) subtype

    Drug: Dalpiciclib · Drug: Goserelin · Drug: Letrozole

  • Active comparator
    L1-2

    If patients were HR+HER2- with SNF1 subtype

    Drug: Nab paclitaxel · Drug: Carboplatin

  • Active comparator
    L2-2

    If patients were HR+HER2- with SNF2 subtype

    Drug: Nab paclitaxel · Drug: Carboplatin

  • Active comparator
    L3-2

    If patients were HR+HER2- with SNF3 subtype

    Drug: Nab paclitaxel · Drug: Carboplatin

  • Active comparator
    L4-2

    If patients were HR+HER2- with SNF4 subtype

    Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    L4-low-1

    If patients were HR+HER2-low with SNF4 subtype

    Drug: SHR-A1811

  • Active comparator
    L4-low-2

    If patients were HR+HER2-low with SNF4 subtype

    Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    TN1-1

    If patients were triple-negative breast cancer with immunomodulatory (IM) subtype

    Drug: Camrelizumab · Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Active comparator
    TN1-2

    If patients were triple-negative breast cancer with IM subtype

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Experimental
    TN2-1

    If patients were triple-negative breast cancer with basal-like immune suppressed (BLIS) subtype

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Fluzoparib

  • Active comparator
    TN2-2

    If patients were triple-negative breast cancer with BLIS subtype

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Experimental
    TN3-1

    If patients were triple-negative breast cancer with androgen receptor positive HER2 activated (AR HER2) subtype

    Drug: Pyrotinib · Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Active comparator
    TN3-2

    If patients were triple-negative breast cancer with AR HER2 subtype

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Experimental
    TN4-1.1

    If patients were HR-HER2-low

    Drug: SHR-A1811

  • Active comparator
    TN4-2

    If patients were HR-HER2-low

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Experimental
    TN5-1.1

    If patients were triple-negative breast cancer with other subtypes

    Drug: SHR-A1921

  • Active comparator
    TN5-2

    If patients were triple-negative breast cancer with other subtypes

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide

  • Experimental
    H1-1.1

    If patients were HR+HER2+

    Drug: Pyrotinib · Drug: SHR-A1811

  • Active comparator
    H1-2

    If patients were HR+HER2+

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    H2-1.1

    If patients were HR-HER2+

    Drug: Pyrotinib

  • Active comparator
    H2-2

    If patients were HR-HER2+

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    L2-1.2

    If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype

    Drug: SHR-1316 · Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    L3-1.2

    If patients were HR+HER2- with similarity network fusion 3 (SNF3) subtype

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Fluzoparib

  • Experimental
    L4-1.2

    If patients were HR+HER2- with similarity network fusion 4 (SNF4) subtype

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Apatinib

  • Experimental
    TN5-1.2

    If patients were triple-negative breast cancer with other subtypes

    Drug: SHR-1316 · Drug: SHR-A1921

  • Experimental
    H1-1.2

    If patients were HR+HER2+

    Drug: SHR-A1811

  • Experimental
    H2-1.2

    If patients were HR-HER2+

    Drug: Pyrotinib · Drug: SHR-A1811

  • Experimental
    TN4-1.2

    If patients were HR-HER2-low

    Drug: SHR-A1811 · Drug: Camrelizumab · Drug: Famitinib

  • Experimental
    L2-1.1

    If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype

    Drug: Dalpiciclib · Drug: Goserelin · Drug: Letrozole

  • Experimental
    L2-1.3

    If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype

    Drug: SHR-1316 · Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Famitinib

  • Experimental
    L3-1.1

    If patients were HR+HER2- with similarity network fusion 3 (SNF3) subtype

    Drug: Dalpiciclib · Drug: Goserelin · Drug: Letrozole

  • Experimental
    L4-1.1

    If patients were HR+HER2- with similarity network fusion 4 (SNF4) subtype

    Drug: SHR-A1921

  • Experimental
    L5-1

    If patients were HR+HER2-

    Drug: Cyclophosphamide · Drug: HB1801 · Drug: LEM

  • Experimental
    L5-2

    If patients were HR+HER2-

    Drug: Cyclophosphamide · Drug: HB1801 · Drug: LEM

  • Experimental
    L6

    If patients were HR+HER2-low

    Drug: SHR-A1811 · Drug: SHR-1316 · Drug: Famitinib

  • Experimental
    L7

    If patients were HR+HER2-low

    Drug: Famitinib · Drug: TQB2102 · Drug: Benmelstobart

  • Experimental
    L8

    If patients were HR+HER2-

    Drug: TQB2102 · Drug: Anlotinib · Drug: TQB2868

  • Experimental
    L9

    If patients were HR+HER2-low

    Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Ivonescimab

  • Experimental
    TN6-1

    TNBC

    Drug: SHR-A1811 · Drug: SHR-1316 · Drug: Famitinib

  • Experimental
    TN6-2

    TNBC

    Drug: SHR-A1811 · Drug: SHR-1316

  • Experimental
    TN7-1

    If patients were HR-HER2-low

    Drug: TQB2102 · Drug: Benmelstobart

  • Experimental
    TN7-2

    If patients were HR-HER2-low

    Drug: TQB2102 · Drug: Benmelstobart · Drug: Anlotinib

  • Experimental
    TN8

    TNBC

    Drug: TQB2102 · Drug: TQB2868

  • Experimental
    TN9

    TNBC

    Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: paclitaxel

  • Experimental
    H3

    If patients were HER2+

    Drug: JSKN003

  • Experimental
    H4-1

    If patients were HER2+

    Drug: SHR-A1811 · Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    H4-2

    If patients were HER2+

    Drug: SHR-A1811

  • Experimental
    H4-3

    If patients were HER2+

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    H4-4

    If patients were HER2+

    Drug: Pyrotinib · Drug: SHR-A1811

  • Experimental
    H5

    If patients were HER2+

    Drug: SHR-A1811 · Drug: SHR-4602

  • Experimental
    H6-1

    If patients were HER2+

    Drug: SHR-A1811 · Drug: HRS-4508

  • Experimental
    H6-2

    If patients were HER2+

    Drug: SHR-A1811 · Drug: Pertuzumab · Drug: HRS-4508

  • Experimental
    L10

    If patients were HR+HER2-

    Drug: Nab paclitaxel · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: JS207

  • Experimental
    H8-1

    If patients were HR+HER2+

    Drug: SHR-A1811 · Drug: Goserelin · Drug: Letrozole · Drug: HRS-6209

  • Experimental
    H8-2

    If patients were HR+HER2+

    Drug: SHR-A1811 · Drug: Goserelin · Drug: Letrozole

  • Experimental
    TN10

    If patients were TNBC

    Drug: JS207 · Drug: 9MW2821

  • Experimental
    L11

    If patients were HR+HER2-

    Drug: JS207 · Drug: 9MW2821

  • Experimental
    H9

    If patients were HER2+

    Drug: SHR-A1811 · Drug: Pertuzumab · Drug: Trastuzumab · Drug: paclitaxel

  • Experimental
    H10

    If patients were HER2+

    Drug: Pertuzumab · Drug: IBI354

  • Experimental
    TN6-3

    TNBC

    Drug: SHR-A1811 · Drug: SHR-1316 · Drug: Nab paclitaxel · Drug: Carboplatin

  • Experimental
    TN11-1: TNBC patients predicted sensitive to Paclitaxel+Carboplatin+Camrelizumab+Famitinib by AI

    The TN11 arm explores AI-guided multidisciplinary precision therapy in TNBC. Patients are stratified using an established digital pathology-based AI model that predicts sensitivity to the combination therapy of Paclitaxel, Carboplatin, Camrelizumab and Famitinib. Patients predicted to be sensitive (TN11-1) receive this combination therapy directly.

    Drug: Camrelizumab · Drug: Carboplatin · Drug: Famitinib · Drug: paclitaxel

  • Experimental
    TN11-2: TNBC patients predicted non-sensitive to Paclitaxel+Carboplatin+Camrelizumab+Famitinib by AI

    TNBC patients predicted to be non-sensitive (TN11-2) to the combination therapy of Paclitaxel, Carboplatin, Camrelizumab and Famitinib first undergo stereotactic body radiation therapy (SBRT). SBRT is delivered to the primary tumor in 3 fractions of 8 Gy (total 24 Gy) over 3-5 days. Following SBRT, patients receive the combination therapy of Paclitaxel, Carboplatin, Camrelizumab and Famitinib.

    Drug: Camrelizumab · Drug: Carboplatin · Drug: Famitinib · Drug: paclitaxel · Radiation: Stereotactic Body Radiation Therapy (SBRT)

  • Experimental
    L12

    Patients with HR+HER2- breast cancer, clinical stage cT1c-4, cN0-3, M0, with either tumor grade ≥2 or Ki-67 ≥20%. Patients first undergo stereotactic body radiotherapy (SBRT) to the primary tumor, followed by combination therapy of Paclitaxel + Epirubicin + Cyclophosphamide + Camrelizumab + Famitinib.

    Drug: Camrelizumab · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Famitinib · Drug: paclitaxel · Radiation: Stereotactic Body Radiation Therapy (SBRT)

Interventions

07

What researchers measure

Primary outcomes

  1. Pathological complete response rate (pCR)

    Pathological complete response rate

    Time frame: through study completion, up to 24 weeks

Secondary outcomes

  1. invasive disease-free survival (iDFS)

    To determine three-year invasive disease-free survival (iDFS) among the treatment arms

    Time frame: Three-year Post-surgery Follow-up

  2. Overall response rate (ORR)

    Complete response (CR) + partial response (PR)

    Time frame: up to 24 weeks

  3. CTCAE scale (V4.0)

    4\) To evaluate the rate of adverse effects of patient by the standard CTCAE scale (V4.0)

    Time frame: through study completion, an average of 1 year

  4. Evaluate gene expression profile during treatment

    To measure gene expression profile of baseline and sequential tumor samples during treatment, through RNA-seq platform

    Time frame: through study completion, up to 24 weeks

  5. Number of peripheral blood mononuclear cells (PBMC) count during treatment

    To measure number of peripheral blood mononuclear cells (PBMC) count from baseline and sequential blood samples during treatment, through Flow CytoMetry platform

    Time frame: through study completion, up to 24 weeks

Other outcomes

  1. Biomarker analysis

    Tumor tissues, paracancerous tissues, ctDNA, blood, fecal samples, tumor pathological whole slide images and MRI images collected from study participants will be used for discovering exploratory biomarkers. The associations between these biomarkers and treatment responses disease status will be investigated.

    Time frame: through study completion, up to 24 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Zuo WJ, Chen L, Shen Y, Wang ZH, Liu GY, Yu KD, Di GH, Wu J, Li JJ, Shao ZM. Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial. Ther Adv Med Oncol. 2024 Feb 14;16:17588359231225032. doi: 10.1177/17588359231225032. eCollection 2024. PubMed 38362377 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 61 months is close to that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2022
First posted
Oct 17, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Sep 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05582499
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Professor, Fudan University) — Principal investigator
First posted
Oct 17, 2022
Start date
Nov 1, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
May 28, 2026

Study contacts

Zhimin Shao, Professor
Contact
zhimingshao@yahoo.com
+86(021)64175590
Zhimin Shao, Professor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dalpiciclib · Pyrotinib · Trastuzumab rezetecan · Adebrelimab · Camrelizumab · Tizetatug rezetecan · Pertuzumab · Trastuzumab · Goserelin · Letrozole · Albumin-Bound Paclitaxel · Carboplatin · Epirubicin · Cyclophosphamide · Fluzoparib · Apatinib · Famitinib · Docetaxel · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 · Ivonescimab · Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 · Anbenitamab repodatecan · HRS-4508 · SHR-4602 · Paclitaxel · HRS-6209 · Anti-HER2 Antibody-drug Conjugate IBI354

Start the discussion